I agree. My gut feel is that the way they are modifying the anthracycline to reduce cardiotoxicity also reduces the anti-cancer effect. It simply taking away the cytotoxic effects and thus reducing cardiotoxicity.
The ROS production aids the anti-cancer effect and thus preventing this reduces efficacy. Bisantrene has a magic wand that has (i) low cardiotoxicity (ii) protects against cardiotoxicity of other anthracyclines, and (iii) increases anti-cancer effect by way of synergy.
Cardioprotection thread, page-11
-
- There are more pages in this discussion • 597 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
0.105(6.14%) |
Mkt cap ! $309.0M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.96 | $1.75 | $862.1K | 467.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |